S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
NASDAQ:CDXS

Codexis - CDXS Stock Forecast, Price & News

$6.06
-0.05 (-0.82%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.05
$6.43
50-Day Range
$6.06
$8.92
52-Week Range
$6.04
$42.01
Volume
698,693 shs
Average Volume
910,034 shs
Market Capitalization
$396.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.33

Codexis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
252.0% Upside
$21.33 Price Target
Short Interest
Bearish
8.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.67
Upright™ Environmental Score
News Sentiment
1.33mentions of Codexis in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$674,290 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.48) to ($0.86) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

715th out of 1,093 stocks

Industrial Organic Chemicals Industry

15th out of 20 stocks

CDXS stock logo

About Codexis (NASDAQ:CDXS) Stock

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

CDXS Stock News Headlines

Codexis: Q2 Earnings Snapshot
Codexis Shares Slide On CEO Transition
See More Headlines
Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

CDXS Company Calendar

Last Earnings
8/04/2022
Today
9/30/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Industrial organic chemicals
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CDXS
CUSIP
19200510
Employees
261
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.33
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+252.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-21,280,000.00
Pretax Margin
-13.81%

Debt

Sales & Book Value

Annual Sales
$104.75 million
Book Value
$2.53 per share

Miscellaneous

Free Float
60,909,000
Market Cap
$396.89 million
Optionable
Optionable
Beta
1.58

Key Executives

  • Dr. Stephen George Dilly MBBS (Age 62)
    Ph.D., Pres, CEO & Director
    Comp: $75k
  • Mr. Ross Taylor Jr. (Age 59)
    M.B.A., Sr. VP & CFO
    Comp: $667.31k
  • Mr. John J. NicolsMr. John J. Nicols (Age 58)
    Director & Strategic Advisor
    Comp: $1.33M
  • Dr. Karl A. Schoene Ph.D.
    Sr. VP of Devel. & Operations
  • Ms. Asli Aras Ph.D.
    VP & Head of Corp. Devel.
  • Ms. Karen Frechou-Armijo
    Sr. VP & Head of HR
  • Dr. Gjalt Huisman Ph.D.
    Sr. VP of Strategic Devel. & GM of Biotherapeutics
  • Mr. Rob Wilson Ph.D.
    Sr. VP & GM of Performance Enzymes
  • Dr. Stefan Lutz Ph.D.
    Sr. VP of Research
  • Mr. Robert Sato M.B.A.
    Ph.D., Sr. VP of Pharmaceutical Devel., Quality & Regulatory













CDXS Stock - Frequently Asked Questions

Should I buy or sell Codexis stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CDXS shares.
View CDXS analyst ratings
or view top-rated stocks.

What is Codexis' stock price forecast for 2022?

5 brokerages have issued twelve-month price targets for Codexis' shares. Their CDXS share price forecasts range from $19.00 to $25.00. On average, they expect the company's share price to reach $21.33 in the next twelve months. This suggests a possible upside of 252.6% from the stock's current price.
View analysts price targets for CDXS
or view top-rated stocks among Wall Street analysts.

How have CDXS shares performed in 2022?

Codexis' stock was trading at $31.27 at the beginning of 2022. Since then, CDXS stock has decreased by 80.7% and is now trading at $6.05.
View the best growth stocks for 2022 here
.

When is Codexis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our CDXS earnings forecast
.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) posted its earnings results on Thursday, August, 4th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.10. The biotechnology company earned $38.41 million during the quarter, compared to the consensus estimate of $37.86 million. Codexis had a negative trailing twelve-month return on equity of 11.63% and a negative net margin of 14.03%. The business's revenue was up 50.9% compared to the same quarter last year. During the same period last year, the business earned ($0.07) earnings per share.

What guidance has Codexis issued on next quarter's earnings?

Codexis issued an update on its FY 2022 earnings guidance on Thursday, September, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $135.00 million-$141.00 million, compared to the consensus revenue estimate of $137.67 million.

What is John J. Nicols' approval rating as Codexis' CEO?

25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

How do I buy shares of Codexis?

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $6.05.

How much money does Codexis make?

Codexis (NASDAQ:CDXS) has a market capitalization of $396.21 million and generates $104.75 million in revenue each year. The biotechnology company earns $-21,280,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.

How many employees does Codexis have?

The company employs 261 workers across the globe.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.codexis.com. The biotechnology company can be reached via phone at (650) 421-8100, via email at ir@codexis.com, or via fax at 650-421-8102.

This page (NASDAQ:CDXS) was last updated on 9/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.